TN2009000249A1 - Mapk/erk kinase inhibitors - Google Patents

Mapk/erk kinase inhibitors

Info

Publication number
TN2009000249A1
TN2009000249A1 TNP2009000249A TN2009000249A TN2009000249A1 TN 2009000249 A1 TN2009000249 A1 TN 2009000249A1 TN P2009000249 A TNP2009000249 A TN P2009000249A TN 2009000249 A TN2009000249 A TN 2009000249A TN 2009000249 A1 TN2009000249 A1 TN 2009000249A1
Authority
TN
Tunisia
Prior art keywords
mapk
kinase inhibitors
erk kinase
compounds
methods
Prior art date
Application number
TNP2009000249A
Other languages
English (en)
Inventor
Qing Dong
Xianchang Gong
Stephen W Kaldor
Toufike Kanouni
Nicholas Scorah
Michael B Wallage
Feng Zhou
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of TN2009000249A1 publication Critical patent/TN2009000249A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TNP2009000249A 2006-12-20 2009-06-17 Mapk/erk kinase inhibitors TN2009000249A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87091306P 2006-12-20 2006-12-20
PCT/US2007/087913 WO2008079814A2 (fr) 2006-12-20 2007-12-18 Inhibiteurs de mapk/erk kinase

Publications (1)

Publication Number Publication Date
TN2009000249A1 true TN2009000249A1 (en) 2010-10-18

Family

ID=39462025

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000249A TN2009000249A1 (en) 2006-12-20 2009-06-17 Mapk/erk kinase inhibitors

Country Status (35)

Country Link
US (4) US8293901B2 (fr)
EP (1) EP2125810B1 (fr)
JP (1) JP5513127B2 (fr)
KR (1) KR101488467B1 (fr)
CN (1) CN101679411B (fr)
AR (1) AR064640A1 (fr)
AU (1) AU2007337003B2 (fr)
BR (1) BRPI0720525B8 (fr)
CA (1) CA2673647C (fr)
CL (1) CL2007003742A1 (fr)
CO (1) CO6230984A2 (fr)
CR (1) CR10937A (fr)
DK (1) DK2125810T3 (fr)
EA (1) EA016312B1 (fr)
EC (1) ECSP099529A (fr)
ES (1) ES2430966T3 (fr)
GE (1) GEP20125511B (fr)
HR (1) HRP20130684T1 (fr)
IL (1) IL199362A (fr)
JO (1) JO2985B1 (fr)
MA (1) MA31151B1 (fr)
MX (1) MX2009006675A (fr)
MY (1) MY157871A (fr)
NO (1) NO342270B1 (fr)
NZ (1) NZ578310A (fr)
PE (1) PE20090071A1 (fr)
PL (1) PL2125810T3 (fr)
PT (1) PT2125810E (fr)
RS (1) RS52887B (fr)
SI (1) SI2125810T1 (fr)
TN (1) TN2009000249A1 (fr)
TW (1) TWI396538B (fr)
UA (1) UA98479C2 (fr)
WO (1) WO2008079814A2 (fr)
ZA (1) ZA200904682B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790649A1 (fr) * 2005-11-21 2007-05-30 Sanofi-Aventis Dérivés de pyrimidone substitués bicycliques
TW200800997A (en) * 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
AU2007353385A1 (en) * 2006-10-23 2008-11-20 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
SA08280783B1 (ar) * 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
JP5363350B2 (ja) 2007-03-19 2013-12-11 武田薬品工業株式会社 Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
ES2456966T3 (es) * 2007-11-12 2014-04-24 Takeda Pharmaceutical Company Limited Inhibidores de MAPK/ERK cinasa
US20090246198A1 (en) * 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
US20100125138A1 (en) * 2008-11-18 2010-05-20 Takeda Pharmaceutical Company Limited PROCESS FOR MAKING (R)-3-(2,3-DIHYDROXYPROPYL)-6-FLUORO-5-(2-FLOURO-4-IODOPHENYLAMINO)-8-METHYLPYRIDO[2,3-d]PYRIMIDINE-4,7(3H,8H)-DIONE AND INTERMEDIATES THEREOF
JP2013532627A (ja) 2010-07-01 2013-08-19 武田薬品工業株式会社 ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
TWI505828B (zh) * 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
TW201316991A (zh) 2011-06-03 2013-05-01 Millennium Pharm Inc Ｍｅｋ抑制劑與奧諾拉（ａｕｒｏｒａ）ａ激酶選擇性抑制劑之組合
ES2857649T3 (es) 2012-03-01 2021-09-29 Array Biopharma Inc Inhibidores de serina/treonina cinasa
JP2015511632A (ja) * 2012-03-30 2015-04-20 武田薬品工業株式会社 メラノーマの治療におけるｒａｆ阻害剤およびｍｅｋ阻害剤の投与
CA2952992C (fr) * 2014-06-17 2019-05-07 Cisen Pharmaceutical Co., Ltd. Analogue de pyridino [1,2-a] pyrimidone utilise en tant qu'inhibiteur de pi3k/mtor
WO2016009306A1 (fr) * 2014-07-15 2016-01-21 Lupin Limited Composés hétérocyclyles utilisés comme inhibiteurs de mek
KR101671404B1 (ko) * 2014-09-02 2016-11-02 한국원자력의학원 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도
JP2016155776A (ja) * 2015-02-24 2016-09-01 学校法人兵庫医科大学 抗腫瘍効果増強剤および抗腫瘍剤
TWI801394B (zh) * 2017-06-23 2023-05-11 大陸商基石藥業（蘇州）有限公司 作為mek抑制劑的類香豆素環類化合物及其應用
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use
CN113473986B (zh) * 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于治疗皮肤疾病萘啶酮苯胺化合物
TWI825637B (zh) * 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
CN117779203B (zh) * 2024-02-28 2024-05-31 西北工业大学 一种n-苄基-2-甲基-4-硝基苯胺单晶及其制备方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5430148A (en) 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
ID30439A (id) 1999-01-13 2001-12-06 Warner Lambert Co Benzoheterosiklus dan penggunaannya sebagai penghambat mek
PA8510701A1 (es) 2000-01-25 2002-12-11 Warner Lambert Co PIRIDO [2,3-d] PIRIMIDIN-2,7-DIAMINAS INHIBIDORES DE CINASAS
ES2461854T3 (es) 2000-07-19 2014-05-21 Warner-Lambert Company Llc Ésteres oxigenados de ácidos 4-yodofenilamino-benzhidroxámicos
JP4524072B2 (ja) 2000-10-23 2010-08-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規化合物
US6825180B2 (en) 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
RU2300528C2 (ru) 2002-03-13 2007-06-10 Эррэй Биофарма, Инк. N3-алкилированные бензимидазольные производные в качестве ингибиторов мек
TWI338685B (en) 2002-03-13 2011-03-11 Array Biopharma Inc N3 alkylated benzimid azole derivatives as mek inhibitors
RU2330851C9 (ru) 2003-05-23 2008-10-20 Центарис Гмбх ПИРИДО[2,3-b]ПИРАЗИНОВЫЕ ПРОИЗВОДНЫЕ, ЛЕКАРСТВЕННОЕ СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ ИЛИ НАРУШЕНИЯ, КОТОРЫЕ ОБУСЛОВЛЕНЫ НЕПРАВИЛЬНО НАПРАВЛЕННЫМИ ПРОЦЕССАМИ КЛЕТОЧНОЙ СИГНАЛЬНОЙ ТРАНСДУКЦИИ, СПОСОБ ПОЛУЧЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА
AU2003277715A1 (en) 2003-07-03 2005-01-21 Sunghag Koo Ferment ginseng oil
ES2331246T3 (es) 2003-07-24 2009-12-28 Warner-Lambert Company Llc Derivados de benzamidazol como inhibidores del mek.
CN1860118A (zh) 2003-07-29 2006-11-08 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
WO2005051300A2 (fr) 2003-11-19 2005-06-09 Array Biopharma Inc. Inhibiteurs bicycliques de mek et leurs procedes de production
DE602005004286T2 (de) 2004-06-11 2009-01-02 Japan Tobacco Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyridoä2,3-düpyrimidinderivate und verwandte verbindungen zur behandlung von krebs
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
DE102004054215A1 (de) 2004-11-10 2006-05-11 Merck Patent Gmbh Pyridopyrimidinonderivate
EP1828184B1 (fr) 2004-12-01 2009-09-16 Merck Serono SA Dérivés de [1,2,4]triazolo[4,3-a]pyridine pour le traitement de maladies hyperprolifératives
JP2009543867A (ja) 2006-07-17 2009-12-10 メルク エンド カムパニー インコーポレーテッド 抗ｈｉｖ剤としての１−ヒドロキシナフチリジン化合物
AU2007353385A1 (en) * 2006-10-23 2008-11-20 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
EP2094698A1 (fr) 2006-11-09 2009-09-02 F. Hoffmann-Roche AG Dérivés de 6-phényl-pyrido [2,3-d]pyrimidine-7-one substitués utilisés comme inhibiteurs de la kinase et méthodes d'utilisation de ceux-ci
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
ES2456966T3 (es) 2007-11-12 2014-04-24 Takeda Pharmaceutical Company Limited Inhibidores de MAPK/ERK cinasa
US20090246198A1 (en) 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
US20100125138A1 (en) * 2008-11-18 2010-05-20 Takeda Pharmaceutical Company Limited PROCESS FOR MAKING (R)-3-(2,3-DIHYDROXYPROPYL)-6-FLUORO-5-(2-FLOURO-4-IODOPHENYLAMINO)-8-METHYLPYRIDO[2,3-d]PYRIMIDINE-4,7(3H,8H)-DIONE AND INTERMEDIATES THEREOF

Also Published As

Publication number Publication date
US20100130518A1 (en) 2010-05-27
KR101488467B1 (ko) 2015-01-30
MA31151B1 (fr) 2010-02-01
CN101679411A (zh) 2010-03-24
MX2009006675A (es) 2009-08-12
ECSP099529A (es) 2009-08-28
PE20090071A1 (es) 2009-04-04
ES2430966T3 (es) 2013-11-22
AU2007337003A1 (en) 2008-07-03
EA200970605A1 (ru) 2009-12-30
WO2008079814A3 (fr) 2008-09-04
US20110065733A1 (en) 2011-03-17
AR064640A1 (es) 2009-04-15
US8293901B2 (en) 2012-10-23
US20120202999A1 (en) 2012-08-09
EA016312B1 (ru) 2012-04-30
CA2673647C (fr) 2016-02-09
AU2007337003A2 (en) 2009-07-30
CA2673647A1 (fr) 2008-07-03
BRPI0720525B1 (pt) 2020-03-03
BRPI0720525B8 (pt) 2021-05-25
PT2125810E (pt) 2013-07-29
JP5513127B2 (ja) 2014-06-04
TWI396538B (zh) 2013-05-21
MY157871A (en) 2016-07-29
WO2008079814A2 (fr) 2008-07-03
US8030317B2 (en) 2011-10-04
CN101679411B (zh) 2013-04-17
EP2125810A2 (fr) 2009-12-02
CL2007003742A1 (es) 2008-06-13
KR20090091353A (ko) 2009-08-27
AU2007337003B2 (en) 2013-05-02
UA98479C2 (en) 2012-05-25
JO2985B1 (ar) 2016-09-05
ZA200904682B (en) 2010-09-29
HRP20130684T1 (en) 2013-10-11
SI2125810T1 (sl) 2013-09-30
JP2010514680A (ja) 2010-05-06
RS52887B (en) 2014-02-28
US20080255160A1 (en) 2008-10-16
PL2125810T3 (pl) 2013-09-30
CR10937A (es) 2009-11-20
EP2125810B1 (fr) 2013-04-24
GEP20125511B (en) 2012-05-10
NZ578310A (en) 2012-01-12
IL199362A (en) 2013-07-31
DK2125810T3 (da) 2013-07-29
TW200835496A (en) 2008-09-01
NO20092692L (no) 2009-09-16
CO6230984A2 (es) 2010-12-20
NO342270B1 (no) 2018-04-30
US8470837B2 (en) 2013-06-25
BRPI0720525A2 (pt) 2014-01-07

Similar Documents

Publication Publication Date Title
TN2009000249A1 (en) Mapk/erk kinase inhibitors
WO2008115890A3 (fr) Inhibiteurs de mapk/erk kinase
WO2009146034A3 (fr) Inhibiteurs de kinases mapk/erk et procédés d’utilisation de ceux-ci
TN2010000131A1 (en) Polo-like kinase inhibitors
WO2008079787A8 (fr) Activateurs de glucokinase
MY150542A (en) Cmet inhibitors
WO2007117995A3 (fr) Inhibiteurs de kinase
WO2007104034A3 (fr) Activateurs de la glucokinase
WO2008116107A3 (fr) Activateurs de glucokinase
MY146989A (en) Kinase inhibitors
ATE479687T1 (de) Kinaseinhibitoren
WO2010008847A3 (fr) Inhibiteurs de pi3k/m tor
WO2008055236A3 (fr) Inhibiteurs de kinase mapk/erk
MX339476B (es) Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
PT2470546E (pt) Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor
WO2007143434A3 (fr) Activateurs de glucokinase
MY152749A (en) Pyrazole and fused pyrazole glucokinase activators
WO2010111626A3 (fr) Inhibiteurs de la poly(adp-ribose)polymérase (parp)
WO2008054956A3 (fr) Inhibiteurs de kinases
TN2011000207A1 (en) Akt and p70 s6 kinase inhibitors
TN2009000151A1 (en) Mapk/erk kinase inhibitors
WO2008045834A3 (fr) Inhibiteurs de kinases
WO2009129401A8 (fr) Inhibiteurs de kinases
TN2009000130A1 (en) Kinase inhibitors
WO2008089005A3 (fr) Inhibiteurs de rénine